Royal Bank of Canada Reiterates Outperform Rating for BioCryst Pharmaceuticals (NASDAQ:BCRX)

BioCryst Pharmaceuticals (NASDAQ:BCRX)‘s stock had its “outperform” rating reaffirmed by research analysts at Royal Bank of Canada in a research report issued on Tuesday, Benzinga reports. They presently have a $10.00 price objective on the biotechnology company’s stock. Royal Bank of Canada’s price objective indicates a potential upside of 29.37% from the company’s current price.

BCRX has been the topic of several other reports. HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 6th. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday. JMP Securities lifted their price target on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 6th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $14.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday. One analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.67.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $7.73 on Tuesday. The firm has a market capitalization of $1.60 billion, a PE ratio of -12.67 and a beta of 1.89. BioCryst Pharmaceuticals has a 52-week low of $4.03 and a 52-week high of $8.88. The firm has a fifty day moving average of $7.80 and a 200 day moving average of $6.98.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. The company’s revenue was up 35.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.19) earnings per share. On average, sell-side analysts forecast that BioCryst Pharmaceuticals will post -0.37 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BCRX. CWM LLC grew its stake in shares of BioCryst Pharmaceuticals by 200.0% in the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 3,772 shares during the last quarter. Signaturefd LLC boosted its stake in BioCryst Pharmaceuticals by 560.5% in the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,599 shares in the last quarter. Seven Eight Capital LP purchased a new stake in BioCryst Pharmaceuticals during the 1st quarter valued at about $57,000. Mirae Asset Global Investments Co. Ltd. grew its position in BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares during the last quarter. Finally, Natixis increased its stake in BioCryst Pharmaceuticals by 400.6% during the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 9,350 shares in the last quarter. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.